Variation: change to the terms of a marketing authorisation
A variation is a change to the terms of a marketing authorisation, classified by its impact as Type IA, Type IB or Type II, or as an extension.
Also known as: variation to a marketing authorisation, post-approval change, post-authorisation change
4 min readUpdated
Reviewed by Gosia Luksza, CEO at Regunaut
At a glance
- Legal basis
- Commission Regulation (EC) No 1234/2008
- Categories
- Type IA, IAIN, IB and II, plus extensions
- Classified by
- Annex II and the Commission guidelines applying from 15 January 2026
- Who handles it
- EMA, the reference member state or the national authority
How it works
Every marketing authorisation rests on a dossier, and the holder must keep both up to date. Article 23 of Directive 2001/83/EC and Article 16 of Regulation (EC) No 726/2004 require the holder to take account of scientific and technical progress and to introduce the changes this calls for, and any change to the content of the dossier or to the terms of the authorisation is a variation. Commission Regulation (EC) No 1234/2008, the Variations Regulation, sets the rules for centrally authorised products, for products authorised through the mutual recognition and decentralised procedures and, since Chapter IIa was added in 2012, for purely national authorisations.
The Regulation sorts changes by their potential impact on quality, safety and efficacy. A Type IA variation has minimal or no impact and is implemented first and notified afterwards, immediately in the case of Type IAIN. A Type II variation may have a significant impact and needs approval before it is implemented. A Type IB variation is everything in between and is the default for a change that nothing else classifies; it is notified and may be implemented after 30 days without objection. Changes listed in Annex I, such as a new strength, pharmaceutical form or route of administration, are extensions and go through the procedure of the initial authorisation. An urgent safety restriction is the exception that lets a holder or an authority act first, with the variation application following within 15 days.
Classification follows a fixed order: Annex II of the Regulation, then the Annex to the Commission guidelines that apply from 15 January 2026, which lists changes in four chapters (E for administrative changes, Q for quality, C for safety, efficacy and pharmacovigilance, M for plasma and vaccine antigen master files) with the conditions and documents for each, then the recommendations published under Article 5. Who handles the variation depends on how the product was authorised: EMA for centrally authorised products, the reference member state with the concerned member states for mutual recognition and decentralised products, and the national authority otherwise. Several changes can travel together through grouping, and the same change across several authorisations through super-grouping or worksharing. The variation classification guide works through the rules step by step.
Some changes sit outside the system. A transfer of the authorisation to another holder is excluded from the Regulation, and a change to the labelling or package leaflet that does not touch the SmPC is notified under Article 61(3) of the Directive instead.
What goes wrong
A category chosen from the title of a change without reading its conditions; a Type IB or Type II change implemented before acceptance; changes made in the quality system that never reach regulatory affairs, so the dossier and the factory drift apart; the same change filed differently in different countries; and product information updates that are approved but never reach the printed pack. Volume is the underlying problem: a large portfolio produces a steady flow of variations, each with its own clock, fee and national implementation step.
Timing
Type IA changes are notified within 12 months of implementation in an annual update, or immediately for Type IAIN, and reviewed within 30 days. A Type IB notification is deemed accepted after 30 days without an unfavourable opinion. A Type II application is assessed in 60 days, extended to 90 days for a new indication and shortened for urgent safety issues, with clock-stops for supplementary information. An extension follows the timetable of a new application.
What teams do with it in Regunaut
Jobs in the platform that turn on Variation, each part of a wider workflow.
- WorkbenchClassify a variationDescribe the change and see which variation type it is, with the regulation and the classification guideline cited.Part of Variations & CMC changes
- Workbench quick task · CMCCompare EU and US change filingsExplore reporting routes for a tighter dissolution specification.Part of Variations & CMC changes
- Workbench quick task · CMCAssess a manufacturing site changeMap the proposed transfer to filing options and evidence needs.Part of Variations & CMC changes
What the 2026 EU pharma package changes
Under the new pharma package (not yet in force), applications for variations to national authorisations are made electronically in EMA formats, categories are set by risk in Commission delegated acts, and some changes may be made as updates of the holder's information in a database; see variations changes.
Variation: common questions
What is a variation in regulatory affairs?
A variation is any change to the terms of a marketing authorisation or to the dossier behind it after the product has been authorised: a new manufacturer, a tightened specification, a safety update to the SmPC, a new indication. In the EU, Commission Regulation (EC) No 1234/2008 defines the categories and the procedure for each.
What are the types of variations in the EU?
There are three types and one separate category. Type IA is a minor change with minimal or no impact, notified after implementation (Type IAIN immediately). Type IB is a minor change notified before implementation, with a 30-day wait. Type II is a major change that needs prior approval. Extensions, such as a new strength or pharmaceutical form, are assessed like a new application.
Who decides how a variation is classified?
The holder proposes the category from Annex II of the Regulation, the Commission's classification guideline and published Article 5 recommendations, and the authority checks it at validation. For a change that none of these covers, the holder can request a classification recommendation, delivered within 60 days; without one, the change is Type IB by default under Article 3(2).
Guides that cover Variation
- Transferring a marketing authorisation in the EU: procedure, documents and timelinesMAH transfers step by step: transfer versus change of name, the 30-day centralised procedure under Regulation (EC) No 2141/96, national transfers for MRP and DCP products, the documents, day-one obligations and the packaging changeover.
- How to classify a variation under Regulation (EC) No 1234/2008Type IA, IA IN, IB, II or extension: the classification rules, the default to Type IB, timelines per type, grouping and worksharing, common mistakes and what Article 94 of the agreed directive changes.
Sources
- EUR-Lex: Commission Regulation (EC) No 1234/2008 concerning the examination of variations to the terms of marketing authorisations, consolidated text of 1 January 2025
- EUR-Lex: Communication from the Commission, Guidelines on the details of the various categories of variation (C/2025/5045, applying from 15 January 2026)
- EUR-Lex: Directive 2001/83/EC on the Community code relating to medicinal products for human use, consolidated text of 1 January 2025